MedTrace Logo

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

NCT02504541 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2018-03-30

Study results available
· View outcomes & findings →

Summary

Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.

Conditions

  • Hypogonadism

Interventions

COMBINATION_PRODUCT

Testosterone enanthate auto-injector

Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels

Sponsors & Collaborators

  • Antares Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Bedel, MD · Prestige Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02504541 on ClinicalTrials.gov